bromopyruvate has been researched along with gemcitabine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bauer, N; Bazhin, AV; Fan, P; Gladkich, J; Gross, W; Haberkorn, U; Herr, I; Isayev, O; Liu, L; Mattern, J; Mollenhauer, M; Nwaeburu, CC; Rausch, V; Rückert, F; Schönsiegel, F; Zach, S; Zhang, Y | 1 |
1 other study(ies) available for bromopyruvate and gemcitabine
Article | Year |
---|---|
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Chick Embryo; Deoxycytidine; Female; Gemcitabine; Glucose; Glycolysis; Humans; Immunohistochemistry; Isoenzymes; L-Lactate Dehydrogenase; Mice, Inbred Strains; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyruvates; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |